Plozasiran can be used as an option to treat genetically confirmed familial chylomicronaemia syndrome in adults, only if response to diet and conventional triglyceride-lowering treatments (such as statins… read more.
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results… read more.
Postmenopausal women are at greater risk for multiple health issues, such as hip fractures and urinary tract infections (UTIs), due to estrogen loss. Vaginal estrogen is used to… read more.
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy… read more.
AbbVie announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease (CD)…. read more.
A next-generation total-body PET/CT scanner can produce diagnostic-quality images in as little as one minute of scanning, according to research presented today at the 39th Annual Congress of… read more.
ALK announced positive topline results from the phase 3 bridging trial evaluating the efficacy and safety of its house dust mite (‘HDM’) sublingual immunotherapy (‘SLIT’) tablet, Acarizax, in… read more.
Johnson & Johnson announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six… read more.
Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication… read more.
Ionis Pharmaceuticals, Inc partner, GSK plc, announced that the FDA has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide… read more.
Mirum Pharmaceuticals, Inc. announced positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ (zilurgisertib), an oral activin receptor-like kinase 2 (ALK2) inhibitor, in pediatric patients… read more.
Alvotech announced that the FDA has approved a new manufacturing process for SIMLANDI (adalimumab-ryvk), Alvotech’s biosimilar to Humira (adalimumab). The FDA approval allows Alvotech to introduce Process 2.0… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
